Plus Therapeutics (FRA:XMP1) Total Liabilities: €6.88 Mil (As of Mar. 2026)


FRA:XMP1 Plus Therapeutics Inc FRA:XMP1
22 GF Score
Price €3.38
! 2 Warning Signs
View Full Analysis

What is Plus Therapeutics Total Liabilities?

Plus Therapeutics FRA:XMP1 -3.01% 22 Total Liabilities is €6.88 Mil as of Mar. 2026. GuruFocus rates FRA:XMP1 with a GF Score™ of 22/100. The stock has 2 warning signs investors should review.

Plus Therapeutics's Total Liabilities for the quarter that ended in Mar. 2026 was €6.88 Mil.

Plus Therapeutics's quarterly Total Liabilities declined from Sep. 2025 (€11.60 Mil) to Dec. 2025 (€10.53 Mil) and declined from Dec. 2025 (€10.53 Mil) to Mar. 2026 (€6.88 Mil).

Plus Therapeutics's annual Total Liabilities increased from Dec. 2023 (€11.68 Mil) to Dec. 2024 (€14.88 Mil) but then declined from Dec. 2024 (€14.88 Mil) to Dec. 2025 (€10.53 Mil).

Plus Therapeutics Total Liabilities Historical Data

* Premium members only.

The historical data trend for Plus Therapeutics's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Plus Therapeutics Total Liabilities Chart

Plus Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 9.86 16.45 11.68 14.88 10.53

Plus Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 33.02 6.34 11.60 10.53 6.88
FRA:XMP1
22GF Score
Plus Therapeutics Inc FRA:XMP1
Total Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Plus Therapeutics Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Plus Therapeutics's Total Liabilities for the fiscal year that ended in Dec. 2025 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=10.516+(0.013+-9.8879238130678E-17
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=10.53

Total Liabilities=Total Assets (A: Dec. 2025 )-Total Equity (A: Dec. 2025 )
=13.942-3.413
=10.53

Plus Therapeutics's Total Liabilities for the quarter that ended in Mar. 2026 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=6.881+(0+0
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=6.88

Total Liabilities=Total Assets (Q: Mar. 2026 )-Total Equity (Q: Mar. 2026 )
=17.227-10.346
=6.88

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Liabilities →
What does a Total Liabilities of €6.88 Mil mean?
Plus Therapeutics (FRA:XMP1) has a Total Liabilities of €6.88 Mil as of Mar. 2026. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Plus Therapeutics and its competitors.
Is Plus Therapeutics' Total Liabilities too high?
Plus Therapeutics' current Total Liabilities is €6.88 Mil. Overall, Plus Therapeutics has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does Plus Therapeutics' Total Liabilities compare to GRCE and NNVC?
Plus Therapeutics' Total Liabilities of €6.88 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Biotechnology company?
A good Total Liabilities depends on the Biotechnology industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Plus Therapeutics and its competitors. Plus Therapeutics's current Total Liabilities is €6.88 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Plus Therapeutics stock overvalued right now?
Plus Therapeutics (FRA:XMP1) has a current Total Liabilities of €6.88 Mil. The current Total Liabilities is €6.88 Mil. Plus Therapeutics' overall GF Score™ is 22/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For Plus Therapeutics (FRA:XMP1), the current Total Liabilities is €6.88 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Plus Therapeutics Business Description

Other Exchanges PSTV:USA
Address 6420 Levit Green Boulevard, Suite 210, Houston, TX, USA, 77021
Plus Therapeutics Inc is a clinical-stage pharmaceutical company that focuses on discovering, developing, commercializing and delivering complex treatments for patients with cancer and rare diseases. The company is working on a range of potential products, with its main programs targeting recurrent glioblastoma (GBM) and leptomeningeal metastases (LM). One of its key candidates, rhenium (186Re) obisbemeda, is specifically designed to treat central nervous system (CNS) cancers such as GBM, LM, and pediatric brain cancers (PBC).
22GF Score

Get the complete analysis for FRA:XMP1

Total Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€3.38
Price